Bibliografía del artículo
1. Barquero-Romero J, García Domínguez M, Pérez Miranda M. Efficacy of therapy with anti-CD20 antibody (rituximab) in a patient with autoimmune hemolytic anemia associated. Med Clin (Barc) 124:517-518, 2005.
2. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 69:258-271, 2002.
3. Semple JW, Freedman J. Autoimmune pathogenesis and autoimmune hemolytic anemia. Semin Hematol 42:122-130, 2005.
4. Packman CH, Leddy JP. Acquired hemolytic anemias due to warm reacting autoantibodies. En: Beutler E. Lichtman MA, Coller BS, Kipps TJ, Soligsohn U, editors. William´s Hematology 6th ed. New York: Mcgraw Hill, p. 685, 2001.
5. Packman CH. Hemolytic anemias due to warm reacting autoantibodies. Blood Rev 22:17-31, 2008.
6. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 141:149-169, 2008.
7. Karasawa M. Autoimmune hemolytic anemia. Nippon Rinsho 66:520-523, 2008.
8. King KE, Ness PM. Treatment of autoimmune haemolytic anemia. Semin Hematol 42:131-136, 2005.
9. Valent P, Lechner K. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr 120:136-151, 2008.
10. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chirmeric antiCD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952-957, 2001.
11. Maloisel F, Andres E, Zimmer J, y col. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 116:590-594, 2004.
12. Petz LD. Treatment of autoimmune hemolytic anemias. Curr Opin Hematol 8:411-416, 2001.
13. Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 119:1198-1208, 1993.
14. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect 43,182-186, 2001.
15. Berentsen S. Rituximab for the treatment of autoimmune cytopenias. Haematologica 92:1589-1596, 2007.
16. D'Arena G, Taylor RP, Cascavilla N, Lindorfer MA. Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocr Metab Immune Disord Drug Targets 8:62-68, 2008.
17. Sokol RJ, Booker DJ, Stamps R. The pathology of autoimmune haemolytic anaemia. J Clin Pathol 45:1047-1052, 1992.
18. Salama A, Mueller-Eckhardt C. Autoimmune haemolytic anaemia in childhood associated with non-complement binding IgM autoantibodies. Br J Haematol 65:67-71, 1987.
19. Berentsen S, Ulvestad E, Langholm R, y col. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 91:460-466, 2006.
20. Gertz MA. Cold agglutinin disease. Haematologica 91:439-441, 2006.
21. Petz LD. Cold antibody autoimmune hemolytic anemias. Blood Rev 22:1-15, 2008.
22. Berentsen S, Beiske K, Tjønnfjord GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology 12:361-370, 2007.
23. Berentsen S, Bo K, Shammas FV, Myking AO, Ulvestad E. Chronic cold agglutinin disease of the "idiopathic" type is a premalignant or low grade malignant lymphoproliferative disease. APMIS 105:354-362, 1997.
24. Berentsen S, Ulvestad E, Gjertsen BT, y col. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 103:2925-2928, 2004.
25. Finazzi G. Rituximab in autoimmune cytopenias: for which patients? Haematologica 87:113-114, 2002.
26. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 61:922-924, 2002.
27. Zoppi M, Oppliger R, Althaus U, Nydegger U. Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionsther Transfusionsmed 20:19-22, 1993.
28. Jacobs A. Cold agglutinin hemolysis responding to fludarabine therapy. Am J Hematol 53:279-280, 1996.
29. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 72:79-88, 2004.
30. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 78:1340-1346, 2003.
31. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 58:299-309, 2004.
32. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48:1484-1492, 2003.
33. McLaughlin P, Grillo-López AJ, Link BK, y col. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
34. Maloney DG, Liles TM, Czerwinski DK, y col. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994.
35. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63:803-843, 2003.
36. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 10:548-551, 1998.
37. Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 66:791-820, 2006.
38. Edwards JC, Szczepanski L, Szechinski J, y col. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581, 2004.
39. Cohen SB, Emery P, Greenwald MW, y col. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-2806, 2006.
40. Emery P, Fleischmann R, Filipowicz-Sosnowska A, y col. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebocontrolled, dose-ranging trial. Arthritis Rheum 54:1390-1400, 2006.
41. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456-473, 2005.
42. Mabthera: Summary of product characteristics (online). Available from URL: www.emea.eu.int/#.
43. Goldberg SL, Pecora AL, Alter RS, y col. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486-1488, 2002.
44. Steurer M, Clausen J, Gotwald T, y col. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation 76:435-436, 2003.
45. Aksoy S, Harputluoglu H, Kilickap S, y col. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48:1307-1312, 2007.
46. Freim Wahl SG, Folvik MR, Torp SH. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature. Clin Neuropathol 26:68-73, 2007.
47. Kranick SM, Mowry EM, Rosenfeld MR. Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma. Neurology 69:704-706, 2007.
48. Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 61:863-866, 2002.
49. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48:1484-1492, 2003.
50. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17:550-557, 2005.
51. Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 169:107-121, 1999.
52. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 3:86-95, 2007.
53. Carter RH. B cells in health and disease. Mayo Clin Proc 81:377-384, 2006.
54. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20:517-527, 2004.
55. Cohen SB. B-cell depletion for rheumatic diseases: where are we? MedGenMed 7:72, 2005.
56. Pulik M, Genet P, Lionnet F, Touahri T. Treatment of primary chronic cold agglutinin disease with rituximab: maintenance therapy may improve the results. Br J Haematol 117:998-999, 2002.
57. Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, Rai KR. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 16:2092-2095, 2002.
58. Zaja F, Vianelli N, Sperotto A, y col. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 44: 1951-1955, 2003.
59. Zecca M, Nobili B, Ramenghi U, y col. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857-3861, 2003.
60. Schöllkopf C, Kjeldsen L, Bjerrum OW, y col. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 47,253-260, 2006.
61. D'Arena G, Califano C, Annunziata, M, y col. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol 79:53-58, 2007.
62. Calvo-Villas JM, Cuesta Tovar J, Carreter de Granda E, Sicilia Guillén F. Delayed response to rituximab of cold agglutinin haemolytic disease. An Med Interna 23:224-8, 2006.
63. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511-1513, 2001.
64. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 90:1273-1274, 2005.
65. Trapè G, Fianchi L, Lai M, y col. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 88:223-225, 2003.
66. Cabrera JR, Peñalver FJ, Millán I, y col. Mabthera (Rituximab) in the Treatment of 34 Adult Patients with Refractory Autoimmune Hemolytic Anemia (AIHA). Blood 104:1619 (abstract), 2004.
67. Rao A, Kelly M, Musselman M, y col. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 50:822-825, 2008.
68. Martínez Velasco E, Gómez Castillo JJ, Fernández Megía MJ, González Joga B, Barreda Hernández D, Gómez Roncero MI. The effectiveness of rituximab in refractory autoimmune thrombocytopenic purpura and haemolytic anaemia. Farm Hosp 31:124-127, 2007.